These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8276650)

  • 21. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.
    Takada M; Fukuoka M; Kawahara M; Sugiura T; Yokoyama A; Yokota S; Nishiwaki Y; Watanabe K; Noda K; Tamura T; Fukuda H; Saijo N
    J Clin Oncol; 2002 Jul; 20(14):3054-60. PubMed ID: 12118018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
    Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer.
    Carlson RW; Sikic BI; Gandara DR; Hendrickson CG; Wittlinger PS; Shields JA; Wong PP; White JE; Meakin CJ; McWhirter KM
    Cancer; 1991 Sep; 68(5):948-58. PubMed ID: 1655219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of low-dose chest irradiation before chemotherapy on the rate of local failure in small-cell lung cancer.
    Hösli P; Bonnefoi H; Mirimanoff RO; Mermillod B; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 May; 41(2):287-9. PubMed ID: 9607343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
    Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
    Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
    N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.
    Hasan S; Renz P; Turrisi A; Colonias A; Finley G; Wegner RE
    Lung Cancer; 2018 Oct; 124():283-290. PubMed ID: 30268474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
    Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
    Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
    Kamath SS; McCarley DL; Zlotecki RA
    Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
    Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases.
    Shaw EG; Su JQ; Eagan RT; Jett JR; Maksymiuk AW; Deigert FA
    J Clin Oncol; 1994 Nov; 12(11):2327-32. PubMed ID: 7964948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial.
    Kraft A; Arnold H; Zwingers T; Bodemann H; von Bültzingslöwen F; Hinkelbein W; Wannenmacher M
    Onkologie; 1990 Aug; 13(4):253-8. PubMed ID: 2172884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.